Company Analysis
Sign in

MeiraGTx Holdings plc (MGTX)

Nasdaq: MGTX · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2018
Full chart Alerts Compare
Grade6.2
◀ Past 7.1● Present 5.9▶ Future 5.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

9 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to MeiraGTx Holdings plc’s names, not what it holds today.

Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against none in 2024 and 2 in 2023
Applications published
25
4 of them in 2025
Names they are printed under
5
a subsidiary
By yearGrantedApplications published
'18'19'20'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology5
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
MeiraGTx UK II Limited a subsidiary
named as the applicant on its applications, in GB
0 granted
17 published
MeiraGTX UK II Limited a subsidiary
GB, as the owner printed on each patent
7 granted
6 published
MeiraGTx Gene Regulation Limited a subsidiary
GB, as the owner printed on each patent
2 granted
0 published
MEIRAGTX GENE REGULATION LIMITED a subsidiary
named as the applicant on its applications, in GB
0 granted
1 published
MeiraGTx Therapeutics, Inc. a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 25, 202512,480,138Modified rAAV capsid protein for gene therapyPharmaceuticalsMeiraGTx Gene Regulation Limited
Sep 16, 202512,416,018Regulation of gene expression by aptamer-mediated modulation of alternative splicingPharmaceuticalsMeiraGTx Gene Regulation Limited
Jul 15, 202512,359,199Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymesBiotechnologyMeiraGTX UK II Limited
Aug 29, 202311,739,333Regulation of gene expression by aptamer-modulated RNase p cleavageBiotechnologyMeiraGTX UK II Limited
Jul 11, 202311,697,815Regulation of gene expression through aptamer-modulated polyadenylationBiotechnologyMeiraGTX UK II Limited
Nov 29, 202211,512,310Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymesBiotechnologyMeiraGTX UK II Limited
Jun 28, 202211,371,077High throughput cell-based screening for aptamersBiotechnologyMeiraGTX UK II Limited
Feb 15, 202211,248,239Regulation of gene expression by aptamer-mediated modulation of alternative splicingPharmaceuticalsMeiraGTX UK II Limited
Dec 3, 201910,494,646Regulation of gene expression by aptamer-mediated modulation of alternative splicingPharmaceuticalsMeiraGTX UK II Limited
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388931REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICINGPharmaceuticalsMEIRAGTX GENE REGULATION LIMITED
Oct 2, 20252025/0302992Polycistronic Expression of Gut PeptidesPharmaceuticalsMeiraGTx UK II Limited
Mar 27, 20252025/0101436APTAMERS AND SMALL MOLECULE LIGANDSOrganic fine chemistryMeiraGTx UK II Limited
Jan 2, 20252025/0002936RETGC Gene TherapyBiotechnologyMeiraGTx UK II Limited
Sep 19, 20242024/0307559KCNV2 GENE THERAPYPharmaceuticalsMeiraGTx UK II Limited
Aug 22, 20242024/0279682AAV Manufacturing MethodsBiotechnologyMeiraGTX UK II Limited
Jun 20, 20242024/0197523MOTORIZED INJECTION SYSTEM AND METHODS OF USEMedical technologyMeiraGTX UK II Limited
Jun 13, 20242024/0191239REGULATION OF GENE EXPRESSION THROUGH APTAMER-MODULATED POLYADENYLATIONBiotechnologyMeiraGTx UK II Limited
Jan 4, 20242024/0002862REGULATION OF GENE EXPRESSION BY APTAMER-MODULATED RNASE P CLEAVAGEBiotechnologyMeiraGTx UK II Limited
Aug 24, 20232023/0265441Aptamers That Bind Thiamine Analogs and DerivativesBiotechnologyMeiraGTx UK II Limited
What it applied for, 2024 to 2025: Biotechnology 4 · Pharmaceuticals 3 · Medical technology 1 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MGTX · research, not advice